<DOC>
	<DOC>NCT01148108</DOC>
	<brief_summary>This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.</brief_summary>
	<brief_title>Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<criteria>relapsed or refractory disease histologically or cytologically confirmed disease characteristic immunophenotypic profiles measurable disease (for lymphoma patients) ECOG performance status of 02 adequate liver and kidney function adequate bone marrow reserves ineligible or unwilling to undergo autologous stem cell transplantation failure to recover from any major surgery within 4 weeks of study entry pregnant or lactating women women of childbearing potential not using reliable and appropriate contraception routine prophylactic use of GCSF required within 2 weeks of study entry Grade 3 or higher peripheral neuropathy history of hepatitis B virus or HIV central nervous system or meningeal involvement by lymphoma or multiple myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>NHL</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Mantle Cell</keyword>
	<keyword>Diffuse Large B Cell</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Telcyta</keyword>
	<keyword>canfosfamide</keyword>
	<keyword>TLK286</keyword>
	<keyword>Prodrug</keyword>
	<keyword>Enzyme activated drug</keyword>
	<keyword>Glutathione Transferase P1-1 activated drug</keyword>
	<keyword>GSTp1-1 activated drug</keyword>
	<keyword>Glutathione Transferase activated drug</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Glutathione analong</keyword>
</DOC>